HIV experts from across the EU will discuss how to reverse the HIV trend and to prepare Europe to achieve the set target of ending AIDS by 2030.
EMCDDA Director Alexis Goosdeel is in Malta today where he will speak at the opening session of a two-day conference on HIV, co-organised by the Maltese EU Presidency and the European Centre for Disease Prevention and Control (ECDC).
As of today, the EMCDDA will be hosting an online Healthy Nightlife Toolbox (HNT), which collects and provides information on good-practice interventions targeting drug and alcohol use and related problems among young people in nightlife settings.
Illicit drug markets have a global reach. This paper provides an overview of EU policies and responses to the production and trafficking of illicit drugs within the international context. It considers the different strategic areas involved, the EU structures concerned, along with some of the key measures currently being implemented by the EU and its international partners. Drug supply reduction actions cut across policy areas. These include illicit drug policy, security, organised crime, and maritime and regional cooperation policy.
The results of a study on national drug trafficking laws and their application in the Member States of the European Union are presented in this report. It is based on an analysis of the national laws and on the opinions of legal practitioners — judges, prosecutors and defence lawyers — from 26 countries. The penalties set out in national laws for trafficking cannabis, amphetamine, cocaine and heroin are compared with the sentencing outcomes expected by the legal practitioners, including penalties imposed and the estimated time likely to be spent in prison.
The EU Drug Markets Report 2016 is the second comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. Taking an evidence-based approach, the report considers the impacts of the drug market on wider society and reviews the markets for cannabis, heroin, cocaine, amphetamine, methamphetamine, MDMA and new psychoactive substances. It also provides concrete action points to inform policy development at EU and national level.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) would like to clarify that, while its activities include reporting on online drug markets, it is not recruiting hackers or rehabilitated traffickers to tackle drug trafficking on the internet, as stated in the various media articles this week.
This week, the EMCDDA embarks on a year-long presidency of a network of nine EU Justice and Home Affairs agencies (‘JHA network’), which play key advisory, operational and coordination roles in implementing EU priorities in the areas of freedom, security and justice.
Under international laws, cultivation, supply and possession of cannabis should be allowed only for ‘medical and scientific purposes’. In general, possession of the drug for personal use should be a crime, to deter use, and most countries make this punishable by imprisonment. In recent years, however, several jurisdictions have reduced their penalties for cannabis users, and some have permitted supply of the drug, allowing us to observe different control models and their consequences.
The latest findings from the largest European project in the emerging science of wastewater analysis are presented today by the Europe-wide SCORE group, in association with the EMCDDA. The project analysed wastewater in over 50 European cities in 18 European countries in March 2016 to explore the drug-taking behaviours of their inhabitants.
Quality standards in drug demand reduction will be the focus of discussions today at an EMCDDA meeting gathering experts from seven countries. The purpose of the meeting is to present how the ‘Council conclusions on the implementation of minimum quality standards in drug demand reduction in the EU’.
On 8 December, the Council adopted its position on a package reforming the legislation on new psychoactive substances (NPS).
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report is based on the indicator’s annual expert meeting, held in Lisbon in June 2016, which brought together national experts from the 28 EU Member States, Norway and Turkey.
EMCDDA Director Alexis Goosdeel is at the Vatican City today where he will speak at a two-day workshop entitled ‘Narcotics: problems and solutions of this global issue’. The event is organised by the Pontifical Academies of Sciences (PAS).
Representatives of candidate, potential candidate and neighbouring countries of the EU are joining members of the EMCDDA’s Reitox network in Lisbon today for the kick-off of the agency’s fifth Reitox week.
The European new psychoactive substances (NPS) market has increased at a speed that established drug control laws struggle to match. Various countries have therefore introduced new legal responses to this phenomenon, based either on existing laws that focused on consumer or health protection or medicinal products, or by developing innovative new legislation. In 2014, the Court of Justice of the European Union ruled that substances are not medicinal products if they do not have beneficial effects on human health, thus restricting the use of such laws for NPS control.
Eurojust and the EMCDDA have released today their first joint publication entitled 'New psychoactive substances in Europe. Legislation and prosecution — current challenges and solutions'.
In this issue: EMCDDA scientific award 2016 | Lisbon Addictions 2017 | New report on drug‑related hospital emergencies | Grounds for hope in treating hepatitis C | EC proposes amendment to EMCDDA founding regulation | New products and services | EMCDDA Director pays official visit to Europol
Following the success of the First European conference on addictive behaviours and dependencies in 2015, the organisers are pleased to announce Lisbon Addictions 2017, to be held in the Portuguese capital from 24–26 October 2017.
The University Institute of Lisbon (ISCTE-IUL) and the EU drugs agency (EMCDDA) will be joining forces next summer to hold the sixth European drugs summer school (EDSS) on ‘Illicit drugs in Europe: demand, supply and public policies’.
Vytenis Andriukaitis, European Commissioner for Health and Food Safety, will visit the EMCDDA today for an update on the agency’s work in the area of public health.
EMCDDA Director Alexis Goosdeel is paying an official visit to Europol today where he will discuss with Director Rob Wainwright opportunities for further cooperation between the two agencies.
Contingency management is a general behavioural intervention technique used in the treatment of drug dependence. This EMCDDA Paper contains a systematic review of studies on the effectiveness of contingency management when used alongside the pharmacological treatment of dependence. The 38 studies concerned related to people using various drugs, and were complemented by three economic studies. The analysis contained in the Paper concludes that contingency management is a feasible and promising adjunct to treatment for drug users.
Ahead of World Mental Health Day on 10 October, the EMCDDA has published a new review on how contingency management can help treat those with substance use disorders.
The third group of students graduating from the European Masters in Drug and Alcohol Studies (EMDAS), will receive their diplomas at a ceremony at the EMCDDA on 23 September.
This brochure provides an overview of the 2015 ESPAD Report which the EMCDDA co-produced with ESPAD.
This report presents the most recent and comprehensive data on substance use among 15- to 16-year-old school students in Europe. Based on the responses from over 90 000 girls and boys, the report documents the levels of use of tobacco, alcohol, cannabis and other substances, as well as the frequency of a number of potentially addictive behaviours, such as online gambling, in 35 European countries. The report also looks at changes in substance use over the past 20 years and at gender differences in substance use and internet behaviour.
Smoking and drinking among 15–16-year-old school students are showing signs of decline, but there are concerns over challenges posed by new drugs and new addictive behaviours.
The latest European data on substance use among 15–16-year-old school students will be released next week (20 September). The findings are based on a 2015 survey in 35 European countries
The Director will present the European Drug Report 2016 on 8 September 2016 to the members of the Civil Liberties, Justice and Home Affairs (LIBE) Committee of the European Parliament. The presentation is scheduled from 15.30 to 16.20 (Brussels times). Live streaming will be availalbe on the website of the European Parliament: www.europarl.europa.eu/ep-live/en/committees/video?event=20160908-1400-COMMITTEE-LIBE